A Study of TAK-279 in Adults With or Without Liver Damage
Recruiting
Takeda
Phase 1
The main aim of this study is to find out how the body processes 1 dose of TAK-279
(pharmacokinetics) in participants with liver problems compared to participants without liver
problems. Other aims are to check for side effects from TAK-279 and to learn how well
participants tolerate 1 dose of TAK-279.
The participants will need to stay at the clinic for 11 days.
A Study of TAK-279 in Adults With or Without Kidney Problems
Active, not recruiting
Takeda
Phase 1
The main aim of this study is to find out how the body processes 1 dose of TAK-279
(pharmacokinetics) in participants with kidney problems compared to participants without
kidney problems. Other aims are to check for side effects from TAK-279 and to learn how well
participants tolerate 1 dose of TAK-279.
The participants will need to stay at the clinic for 11 days.
A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults
Completed
Takeda
Phase 1
The main aim of this study is to find out how the body of a healthy adult processes TAK-279
(pharmacokinetics) when substances that either hinder or help the human metabolism such as
erythromycin, phenytoin and efavirenz are given along with TAK-279. Other aim is to learn
about side effects and how well it is tolerated when TAK-279 is given alone and together with
substances that impact human metabolism.
The participants will need to stay at the clinic for up to 26 days.
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
Recruiting
Takeda
Phase 3
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to
placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be
assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a
placebo). Participants will be in the study for up to 56 weeks.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
